Northstar Advisory Group LLC purchased a new stake in shares of Colgate-Palmolive Company (NYSE:CL - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 14,486 shares of the company's stock, valued at approximately $1,145,000.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Mn Services Vermogensbeheer B.V. lifted its stake in shares of Colgate-Palmolive by 2.8% during the 4th quarter. Mn Services Vermogensbeheer B.V. now owns 299,488 shares of the company's stock worth $23,666,000 after buying an additional 8,069 shares during the last quarter. Columbus Macro LLC bought a new position in Colgate-Palmolive in the 4th quarter valued at about $8,249,000. Private Advisory Group LLC lifted its position in Colgate-Palmolive by 106.7% during the fourth quarter. Private Advisory Group LLC now owns 7,015 shares of the company's stock worth $554,000 after acquiring an additional 3,622 shares during the last quarter. Clarius Group LLC lifted its position in Colgate-Palmolive by 102.8% during the fourth quarter. Clarius Group LLC now owns 5,965 shares of the company's stock worth $471,000 after acquiring an additional 3,024 shares during the last quarter. Finally, ORG Partners LLC boosted its holdings in shares of Colgate-Palmolive by 10.5% during the fourth quarter. ORG Partners LLC now owns 2,348 shares of the company's stock worth $186,000 after acquiring an additional 223 shares during the period. 80.41% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
CL has been the topic of a number of recent research reports. Wells Fargo & Company increased their target price on Colgate-Palmolive from $86.00 to $94.00 and gave the stock an "equal weight" rating in a research note on Sunday, February 1st. Citigroup upped their price objective on Colgate-Palmolive from $95.00 to $105.00 and gave the company a "buy" rating in a report on Monday, February 2nd. Morgan Stanley increased their price objective on Colgate-Palmolive from $87.00 to $100.00 and gave the stock an "overweight" rating in a research report on Monday, February 2nd. Piper Sandler boosted their target price on shares of Colgate-Palmolive from $88.00 to $96.00 and gave the company an "overweight" rating in a research report on Friday, January 30th. Finally, Evercore upped their price target on shares of Colgate-Palmolive from $94.00 to $100.00 and gave the company an "outperform" rating in a research note on Monday, February 2nd. Twelve equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $95.25.
View Our Latest Analysis on Colgate-Palmolive
Insider Activity
In other Colgate-Palmolive news, COO Panagiotis Tsourapas sold 15,000 shares of the stock in a transaction dated Thursday, February 12th. The shares were sold at an average price of $97.81, for a total transaction of $1,467,150.00. Following the sale, the chief operating officer directly owned 10,415 shares in the company, valued at $1,018,691.15. This represents a 59.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Sally Massey sold 15,851 shares of the firm's stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of $95.03, for a total transaction of $1,506,320.53. Following the completion of the transaction, the insider directly owned 13,751 shares in the company, valued at approximately $1,306,757.53. This represents a 53.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 184,683 shares of company stock worth $17,486,693. 0.41% of the stock is owned by company insiders.
Colgate-Palmolive Trading Up 1.5%
Shares of NYSE:CL opened at $85.59 on Tuesday. The business's 50 day simple moving average is $91.13 and its 200 day simple moving average is $83.39. Colgate-Palmolive Company has a 1 year low of $74.54 and a 1 year high of $99.33. The company has a debt-to-equity ratio of 18.82, a current ratio of 0.83 and a quick ratio of 0.54. The company has a market capitalization of $68.67 billion, a P/E ratio of 32.67, a P/E/G ratio of 3.78 and a beta of 0.28.
Colgate-Palmolive (NYSE:CL - Get Free Report) last announced its quarterly earnings data on Friday, January 30th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.91 by $0.04. The firm had revenue of $5.23 billion during the quarter, compared to analysts' expectations of $5.13 billion. Colgate-Palmolive had a return on equity of 353.72% and a net margin of 10.45%.The company's quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.91 EPS. On average, research analysts anticipate that Colgate-Palmolive Company will post 3.75 EPS for the current fiscal year.
Colgate-Palmolive Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.5%. This is a boost from Colgate-Palmolive's previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Monday, April 20th. Colgate-Palmolive's payout ratio is presently 79.39%.
Colgate-Palmolive Company Profile
(
Free Report)
Colgate-Palmolive Company is a global consumer products company with a long history in household and personal care categories. The business traces its roots to the early 19th century and has evolved into a multinational manufacturer and marketer of everyday consumer goods focused on health, hygiene and home care.
The company's core activities center on oral care, personal care, home care and pet nutrition. Its product portfolio includes toothpaste, toothbrushes and mouthwash in oral care; soaps, body washes and deodorants in personal care; dishwashing liquids, surface cleaners and other household products in home care; and scientifically formulated pet foods under its pet nutrition business.
Read More
Want to see what other hedge funds are holding CL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Colgate-Palmolive Company (NYSE:CL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Colgate-Palmolive, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Colgate-Palmolive wasn't on the list.
While Colgate-Palmolive currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.
Get This Free Report